Abstract: Disclosed herein are methods for treating or preventing a disease in mammals having the characteristics of Type 1 diabetes comprising administering insulin or disease suppressive fragments of insulin or analogs thereof in oral or aerosol dosage forms to said mammals. Also disclosed herein are pharmaceutical formulation or dosage forms for use in the methods.

Abstract: Described are methods for treating or preventing type I diabetes and insulitis by oral administration of the bystander antigen glucagon. The methods involve oral administration of glucagon in an amounts that are effective to treat or prevent type I diabetes or insulitis.

Abstract: The invention is directed to a method of treating a T cell-mediated autoimmune disease in animals, including humans, by the oral administration of autoantigens, fragments of autoantigens, or analogs structurally related to those autoantigens, which are specific for the particular autoimmune disease. The method of the invention includes both prophylactic and therapeutic measures.

Abstract: The present invention provides a method of treating or preventing the clinical manifestation of an autoimmune disease having the symptoms of uveoretinitis in a mammal in need of such treatment comprising orally administering to said mammal an effective amount of an autoantigen, e.g., S antigen (S-Ag), and/or biologically active fragments, or analogs thereof specific for uveoretinitis.Also provided is a pharmaceutical formulation useful for treating or preventing uveoretinitis in mammals comprising an effective amount of one or more of the foregoing autoantigen, fragments or analogs.

Abstract: A combination of a mucosally administrable bystander antigen and an orally, enterally, or parenterally administrable methotrexate is employed to make a pharmaceutical formulation and to treat or prevent autoimmune disease.

Abstract: The invention is directed to a method of treating a T cell-mediated autoimmune disease in animals, including humans, by the oral or enteral administration of autoantigens, fragments of autoantigens, or analogs structurally related to those autoantigens, which are specific for the particular autoimmune disease. The method of the invention includes both prophylactic and therapeutic measures.

Abstract: The invention is directed to a method of treating a T cell-mediated autoimmune disease in animals, including humans, by the oral administration of autoantigens, fragments of autoantigens, or analogs structurally related to those autoantigens, which are specific for the particular autoimmune disease. The method of the invention includes both prophylactic and therapeutic measures.

Abstract: Disclosed herein are methods for treating or preventing a disease in mammals having the characteristics of Type 1 diabetes comprising administering insulin or disease suppressive fragments of insulin or analogs thereof in oral or aerosol dosage forms to said mammals. Also disclosed herein are pharmaceutical formulation or dosage forms for use in the methods.

Abstract: A method for suppressing autoimmune response in an afflicted joint in a human. The method involves oral administration of between about 5 and 25 .mu.g per day of type II collagen.

Abstract: The invention is directed to a method of treating multiple sclerosis in animals, including humans, by the oral administration of bovine myelin.

Abstract: Disclosed herein are methods for treating or preventing a disease in mammals having the characteristics of Type 1 diabetes comprising administering insulin or disease suppressive fragments of insulin or analogs thereof in oral or aerosol dosage forms to said mammals. Also disclosed herein are pharmaceutical formulation or dosage forms for use in the methods.

Abstract: Disclosed herein are methods for suppressing allograft rejection in mammals comprising administering to a mammal about to undergo or having undergone allograft surgery an agent selected from the group consisting of splenic tissue from an allograft donor, splenic extracts, cultured lymphocytes from an allograft donor, extracts of said cultured lymphocytes, MHC antigens, transplantation rejection suppressive fragments and analogs of MHC antigens in an oral or aerosol form. Also disclosed herein are pharmaceutical formulations and dosage forms for use in said methods.